314 results about "Enone" patented technology

The present invention concerns methods for stimulating the growth and repair of bone and cartilage using synthetic triterpenoids and tricyclic-bis-enones. Examples of suitable triterpenoids include CDDO, CDDO-Me, CDDO-Im, and CDDO-Ethylamide. Examples of tricyclic-bis-enones include TBE-31 and TBE-34.

The present invention relates to a compound of Antrodia camphorata used to inhibit HBV, in particular to an extract, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone which is isolated from Antrodia camphorata, and its use in inhibiting HBV effectively. The cyclohexenone compound according to the present invention showed cytotoxicity on HBV-secreting human hepatoma cell line HepG2 2.2.15, decreased synthesis of HBV particles, further inhibited synthesis of HbsAg and HbeAg effectively to achieve the goal of HBV inhibition.

Quinone methide derivatives such as 4-benzylidene-2,6-di-tert-butyl-cyclohexa-2,5 dienone are used to inhibit styrene monomer polymerization in the dehydrogenator portion of a styrene monomer production system. The inhibitor contacts the dehydrogenation effluent and does not partition in substantial amounts to the aqueous phase that is separated in the phase separator.

The invention discloses a new compound and the usage, in particular to a 4-hydroxy-2, 3- dimethoxy -6-methyl-5 (3, 7, 11- trimethyl-2, 6, 10-dodecatrien) -2- cyclohexenone (4-hydroxy- 2, 3-dimethoxy -6- methy-5 (3, 7, 11-trimethyl -dodeca-2, 6, 10- trienyl) -cyclohex-2-enone) separated from antrodia camphorate extract and the application in inhibiting the growth of tumor cell. The new compound is firstly seen in antrodia camphorate. The 4-hydroxy-2, 3- dimethoxy -6-methyl-5 (3, 7, 11- trimethyl-2, 6, 10-dodecatrien) -2- cyclohexenone (4-hydroxy- 2, 3-dimethoxy -6- methy-5 (3, 7, 11-trimethyl -dodeca-2, 6, 10- trienyl) -cyclohex-2-enone) separated from antrodia camphorate extract and the application in inhibiting the growth of tumor cell has the advantages of inhibiting the growth of breast cancer, liver cancer and prostate cancer tumor cell, being a component of drug combination inhibiting the growth of the tumor cell at the same time or further being applied in preventing cardiovascular disease or being added into healthy food by right of antioxidant activity.

A liquid crystal aligning agent which can provide liquid crystal aligning capability through exposure to polarized radiation without rubbing and which is used to form a liquid crystal alignment film, a method of forming a liquid crystal alignment film, and a liquid crystal display element having this liquid crystal alignment film. An alignment film is formed from a liquid crystal aligning agent containing a polymer having a polyamic acid ester structure with a conjugated enone structure in the side chain and applying radiation to it from a predetermined direction. Thereby, a liquid crystal display element having high thermal stability in the alignment of liquid crystals and excellent display characteristics can be manufactured.

Process for the preparation of unsaturated 4,5-allene ketones by reaction of tertiary propargyl alcohols with alkenyl alkyl ethers or ketals in the presence of aliphatic sulfonic acids or sulfonic acid salts.

The present invention relates to a compound of Antrodia camphorata used to treat autoimmune diseases, in particular to an extract, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone, isolated from Antrodia camphorata, and its use in alleviating symptoms of autoimmune diseases such as systemic lupus erythematosus (SLE). The cyclohexenone compound according to the present invention helps to decrease proteinuria levels and antinuclear antibody titers in SLE mammals in order to alleviate kidney inflammation and disease, as well as the self-damage caused by antinuclear antibodies. The purpose for prevention and treatment of autoimmune diseases and kidney diseases by the natural, side-effect free substance can then be accomplished.

Disclosed herein are novel antioxidant inflammation modulators, including those of the formula:

wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.

The invention relates to a method for continuously synthesizing ethyl 4-chloroacetoacetates. The method comprises the following steps: pumping a cooled diketene solution into a falling film reactor through a metering pump, and enabling the cooled diketene solution to uniformly form a film through a distributor, and flow into the reactor from a tower top; meanwhile, controlling the flow of chlorine gas through a gas flow meter; introducing the chlorine gas into the reactor through a gas distributor; carrying out a reaction on the diketene and the chlorine gas on the surface of the falling film reactor; after the reaction is finished, enabling reaction liquid to flow out from a tower bottom and enter an esterification reaction kettle; pumping in different alcohols and overflowing into a next esterification reaction kettle to continually react; absorbing hydrogen chloride gas, which is generated in a reaction process, with water; after the reaction is finished, washing with water and neutralizing to remove the residual hydrogen chloride; distilling an organic phase to recycle a solvent and excessive alcohol raw materials to obtain a crude product; rectifying the crude product to obtain an ethyl 4-chloroacetoacetates product. With the adoption of the method, reaction time can be shortened, energy consumption is reduced, polychlorides are controlled, reaction selectivity is improved, rectification is relatively easy, and yield and purity of the product are improved.

The invention relates to a preparation method of terpenoid and lignan substances in eucommia ulmoides bark or eucommia ulmoides leaves and an application of the terpenoid and lignan substances in preparation of senile dementia and AD (Alzheimer disease) treatment drugs or healthcare food. The prepared terpenoid substance in the eucommia ulmoides bark or the eucommia ulmoides leaves is one or more of 1-deoxy-delta4,5-eucommiol, 2,3-dyhydroxyl-delta4,5-eucommiol, 5-hydroxyl-3,4-dihydroxymethyl-2-hydroxyethyl-cyclohex- 1-enone-2'-O-beta-D-glucopyranoside), (6R, 7E, 9R)-megastigma-4,7-dien-3-one-9-O-[beta-D-xylopyranos-yl-(1'-6')-beta-D-glucopyranoside, (6S, 7E, 9R)-megastigma-4,7-dien-3-one-9-O-[beta-D-xylopyranos-yl-(1'-6')-beta-D-glucopyranoside] and the like. The prepared lignan substance in the eucommia ulmoides bark or the eucommia ulmoides leaves is one or more of pinoresinol-4,4'-O-beta-D-bis(glucopyranoside), 8-hydroxyl-pinoresinol-4'-O-beta-D-glucopyranoside, lariciresinol-4,4'-O-beta-D- bis(glucopyranoside) and the like. The terpenoid and lignan substances have common or similar structural units such as eucommiol, megastigmane sesquiterpene, bisepoxylignans, single-epoxy lignans and the like, thereby having the similar treatment effect in a human body.

The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of ovarian cancer cells and be used as a pharmaceutical composition to inhibit the ovarian tumor growth.

The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of pancreatic cancer cells and be used as a pharmaceutical composition to inhibit the pancreatic tumor growth.

A method for reducing the concentration of cyclohexenone in a cyclohexenone containing organic mixture is disclosed. The method includes contacting an organic mixture comprising cyclohexenone with an effective amount of at least one of sulfurous acid, a salt of sulfurous acid, an alkali hydroxide, or a mixture of two or more of these compounds.

This invention relates to a reaction product obtained by ring-opening metathesis polymerization of norbornene ketones functionalized with the residual portion of a vinyl terminated macromonomer.

The invention discloses a preparation method of fosfomycin amine salt, which comprises the following steps of: in organic solvent, enabling fosfomycin phenylethylamine salt to react with isocyanate, isothiocyanate, ketene, dipolymer of isocyanate, dipolymer of isothiocyanate or dipolymer of ketene, and tromethamine; or in the organic solvent, enabling fosfomycin bistromethamine to react with isocyanate, isothiocyanate, ketene, dipolymer of isocyanate, dipolymer of isothiocyanate or dipolymer of ketene. The preparation method provided by the invention has the advantages that the fosfomycin amine salt can be prepared in one step only, a low-temperature ion exchange column is not required, the yield is high, the cost is low, the waste gas, waste water and waste residue are less, the reaction conditions are moderate, the energy consumption is low, the operation is convenient to conduct and the method is suitable for industrial production.

The present application relates to: (a) compounds of Formula (I):

and salts thereof, wherein R¹, R², R³, R⁴, R⁵, R⁶, m, n, X and Y are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use for the treatment and prevention of diseases such as those associated with oxidative stress and inflammation.